US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EA011488B1
(ru)
|
2002-02-01 |
2009-04-28 |
Ариад Джин Терапьютикс, Инк. |
Фосфорсодержащие соединения и их получение
|
MXPA04011384A
(es)
|
2002-05-16 |
2005-02-14 |
Novartis Ag |
Uso de agentes de union del receptor edg en cancer.
|
NZ536558A
(en)
|
2002-05-27 |
2006-07-28 |
Novartis Ag |
Bis-aromatic alkanols
|
PL408347A1
(pl)
|
2002-09-24 |
2014-08-18 |
Novartis Ag |
Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
|
AR044402A1
(es)
|
2003-05-19 |
2005-09-14 |
Irm Llc |
Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
JP4716280B2
(ja)
*
|
2004-03-01 |
2011-07-06 |
テルモ株式会社 |
O−アルキル化ラパマイシン誘導体の製造法
|
GB0417852D0
(en)
*
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7528145B2
(en)
|
2004-10-28 |
2009-05-05 |
Wyeth |
Use of an mTOR inhibitor in treatment of uterine leiomyoma
|
GB0507918D0
(en)
|
2005-04-19 |
2005-05-25 |
Novartis Ag |
Organic compounds
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
PL1909973T3
(pl)
|
2005-07-15 |
2019-01-31 |
Micell Technologies, Inc. |
Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
|
NI200800032A
(es)
|
2005-07-25 |
2009-03-23 |
|
Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
|
WO2007027751A2
(en)
|
2005-08-30 |
2007-03-08 |
University Of Miami |
Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
|
CA2898369C
(en)
|
2005-10-26 |
2017-06-20 |
Novartis Ag |
Novel use of il-1beta compounds
|
EP1942937A1
(en)
|
2005-11-04 |
2008-07-16 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
NO20220050A1
(no)
|
2005-11-21 |
2008-08-12 |
Novartis Ag |
Neuroendokrin tumorbehandling
|
JP2009532503A
(ja)
|
2006-04-05 |
2009-09-10 |
ノバルティス アクチエンゲゼルシャフト |
癌を処置するための治療剤の組合せ
|
ES2540059T3
(es)
|
2006-04-26 |
2015-07-08 |
Micell Technologies, Inc. |
Recubrimientos que contienen múltiples fármacos
|
US8067055B2
(en)
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
JP5603598B2
(ja)
|
2007-01-08 |
2014-10-08 |
ミセル テクノロジーズ、インコーポレイテッド |
生物分解層を有するステント
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
EP2468301A1
(en)
|
2007-05-29 |
2012-06-27 |
Novartis AG |
New indications for anti-IL-1-beta therapy
|
US20100048914A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
WO2009117669A2
(en)
|
2008-03-21 |
2009-09-24 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
US20090253733A1
(en)
*
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
SI2132228T1
(sl)
|
2008-04-11 |
2011-10-28 |
Emergent Product Dev Seatle |
CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
|
CA2721832C
(en)
|
2008-04-17 |
2018-08-07 |
Micell Technologies, Inc. |
Stents having bioabsorbable layers
|
WO2009155475A1
(en)
|
2008-06-20 |
2009-12-23 |
Novartis Ag |
Paediatric compositions for treating1 multiple sclerosis
|
AU2009270849B2
(en)
|
2008-07-17 |
2013-11-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN103204794A
(zh)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
新的盐
|
EP3023433A1
(en)
|
2009-02-05 |
2016-05-25 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
CN102481195B
(zh)
|
2009-04-01 |
2015-03-25 |
米歇尔技术公司 |
涂覆支架
|
EP2419058B1
(en)
|
2009-04-17 |
2018-02-28 |
Micell Technologies, Inc. |
Stents having controlled elution
|
EP2453834A4
(en)
|
2009-07-16 |
2014-04-16 |
Micell Technologies Inc |
MEDICAL DEVICE DISPENSING MEDICINE
|
AU2010279637B2
(en)
|
2009-08-03 |
2012-08-23 |
University Of Miami |
Method for in vivo expansion of T regulatory cells
|
WO2011024168A2
(en)
|
2009-08-26 |
2011-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd |
Sustained release delivery systems for the prevention and treatment of head and neck cancers
|
KR20120115237A
(ko)
|
2009-10-30 |
2012-10-17 |
어리어드 파마슈티칼스, 인코포레이티드 |
암 치료 방법 및 조성물
|
WO2011097103A1
(en)
|
2010-02-02 |
2011-08-11 |
Micell Technologies, Inc. |
Stent and stent delivery system with improved deliverability
|
SG10201502270TA
(en)
|
2010-03-29 |
2015-05-28 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
RU2589696C2
(ru)
|
2010-04-13 |
2016-07-10 |
Новартис Аг |
КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА
|
US20130035343A1
(en)
|
2010-04-16 |
2013-02-07 |
Novartis Ag |
Combination of organic compounds
|
US10232092B2
(en)
|
2010-04-22 |
2019-03-19 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
MX342590B
(es)
|
2010-04-27 |
2016-10-05 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
|
EP2593039B1
(en)
|
2010-07-16 |
2022-11-30 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US20140066439A1
(en)
|
2010-11-10 |
2014-03-06 |
Katholieke Universiteit Leuen, K.U.Leuven R&D |
Osteoclast activity
|
DK2455104T3
(da)
|
2010-11-19 |
2013-10-14 |
Universitaetsklinikum Freiburg |
Biofunktionaliserede stimulusafhængige opløselige PEG-hydrogeler
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
BR112013027486A2
(pt)
|
2011-04-25 |
2017-02-14 |
Novartis Ag |
combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
|
WO2013012689A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
AP2014007680A0
(en)
|
2011-12-02 |
2014-06-30 |
Novartis Ag |
Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
CA2868123A1
(en)
|
2012-03-23 |
2013-09-26 |
The University Of Queensland |
Immunomodulatory agent and uses therefor
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US20150258127A1
(en)
|
2012-10-31 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
JP2016504045A
(ja)
|
2013-01-09 |
2016-02-12 |
ザ ユニバーシティー オブ マイアミThe University Of Miami |
TL1A−Ig融合タンパク質を用いる制御性T細胞の制御のための組成物及び方法
|
PT3300745T
(pt)
|
2013-02-15 |
2019-11-27 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
EP2967803B1
(en)
|
2013-03-12 |
2023-12-27 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
WO2014184734A1
(en)
|
2013-05-14 |
2014-11-20 |
Novartis Ag |
Markers associated with mtor inhibition
|
JP2016519965A
(ja)
|
2013-05-15 |
2016-07-11 |
マイセル・テクノロジーズ,インコーポレイテッド |
生体吸収性バイオメディカルインプラント
|
WO2014200659A1
(en)
|
2013-06-11 |
2014-12-18 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
SG11201600525XA
(en)
|
2013-08-12 |
2016-02-26 |
Tokai Pharmaceuticals Inc |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
WO2015044854A1
(en)
|
2013-09-24 |
2015-04-02 |
Novartis Ag |
Markers associated with mtor inhibition
|
KR20160084438A
(ko)
|
2013-11-13 |
2016-07-13 |
노파르티스 아게 |
면역 반응을 강화하기 위한 mTOR 억제제
|
EP2878312A1
(en)
|
2013-12-02 |
2015-06-03 |
Albert-Ludwigs-Universität Freiburg |
Reversible PEGylation of nanocarriers
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
US10428331B2
(en)
|
2014-01-16 |
2019-10-01 |
Musc Foundation For Research Development |
Targeted nanocarriers for the administration of immunosuppressive agents
|
JP2017505345A
(ja)
|
2014-02-11 |
2017-02-16 |
ノバルティス アーゲー |
がんの処置のためのpi3k阻害剤を含む組合せ医薬
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
CN107073066B
(zh)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
JP6716139B2
(ja)
|
2015-01-19 |
2020-07-01 |
学校法人慶應義塾 |
内耳性難聴治療薬
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US11535665B2
(en)
|
2015-05-13 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
CA3001654A1
(en)
|
2015-11-11 |
2017-05-18 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
WO2017087723A1
(en)
|
2015-11-19 |
2017-05-26 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
JP2019507754A
(ja)
|
2016-02-23 |
2019-03-22 |
キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited |
少なくとも2つの非必須アミノ酸を欠くダイエタリー製品
|
WO2020047527A2
(en)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
AU2017363970A1
(en)
|
2016-11-23 |
2019-06-20 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
JOP20190154B1
(ar)
|
2016-12-22 |
2022-09-15 |
Amgen Inc |
بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
|
KR20190135000A
(ko)
|
2017-02-28 |
2019-12-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Aav 벡터를 기반으로 하는 인플루엔자 백신
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
SI3589730T1
(sl)
|
2017-02-28 |
2024-04-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
|
MX2019010445A
(es)
|
2017-03-03 |
2019-10-24 |
F1 Oncology Inc |
Metodos y composiciones para transducir y expandir linfocitos y regular la actividad de los mismos.
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
CN110770243A
(zh)
*
|
2017-05-02 |
2020-02-07 |
锐新医药公司 |
作为mtor抑制剂的雷帕霉素类似物
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
WO2019012024A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
UY37900A
(es)
|
2017-09-26 |
2019-04-30 |
Novartis Ag |
Nuevos derivados de rapamicina
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
CA3098692A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
MX2020011564A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina unidos a c26 como inhibidores de mtor.
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3802537A1
(en)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
EP3813946B1
(en)
|
2018-06-15 |
2024-05-22 |
Janssen Pharmaceutica NV |
Rapamycin analogs and uses thereof
|
WO2020023418A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
EP3826649A4
(en)
|
2018-07-23 |
2022-07-20 |
Enclear Therapies, Inc. |
METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
EP3860642A1
(en)
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
EP3860643A1
(en)
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3122922A1
(en)
|
2018-12-18 |
2020-06-25 |
Novartis Ag |
Rapamycin derivatives
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
BR112021014479A2
(pt)
|
2019-01-22 |
2021-10-13 |
Aeovian Pharmaceuticals, Inc. |
Moduladores de mtorc e seus usos
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
MX2021011376A
(es)
|
2019-03-26 |
2021-10-13 |
Novartis Ag |
Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
|
EP3952947A1
(en)
|
2019-04-11 |
2022-02-16 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
CN114302880A
(zh)
|
2019-08-02 |
2022-04-08 |
美国安进公司 |
Kif18a抑制剂
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
EP4051678A1
(en)
|
2019-10-28 |
2022-09-07 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
BR112022008565A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
MX2022005708A
(es)
|
2019-11-14 |
2022-06-08 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
BR112022010754A2
(pt)
|
2019-12-05 |
2022-08-23 |
Anakuria Therapeutics Inc |
Análogos de rapamicina e usos dos mesmos
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
CN111317826B
(zh)
*
|
2020-03-19 |
2022-02-11 |
上海交通大学 |
基于金属离子配位自组装构建核酸复合纳米药物及其制备方法和应用
|
CN115776907A
(zh)
|
2020-03-27 |
2023-03-10 |
艾奥维安制药公司 |
Mtorc1调节剂及其用途
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2022014640A1
(ja)
|
2020-07-15 |
2022-01-20 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
WO2022020522A2
(en)
|
2020-07-21 |
2022-01-27 |
Aeovian Pharmaceuticals, Inc. |
Mtorc1 modulators and uses thereof
|
EP4214209A1
(en)
|
2020-09-15 |
2023-07-26 |
Revolution Medicines, Inc. |
Indole derivatives as ras inhibitors in the treatment of cancer
|
WO2022098642A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
EP4256065A2
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
AR124449A1
(es)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
Inhibidores de sos1 y usos de los mismos
|
WO2022187289A1
(en)
|
2021-03-01 |
2022-09-09 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of retroviral particles
|
CA3216004A1
(en)
|
2021-04-23 |
2022-10-27 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
WO2023056399A1
(en)
|
2021-10-02 |
2023-04-06 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023168305A1
(en)
|
2022-03-01 |
2023-09-07 |
Exuma Biotech Corp. |
Viral particles with membrane-bound hyaluronidase
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
CN115340560B
(zh)
*
|
2022-06-14 |
2024-04-02 |
福建省微生物研究所 |
一种西罗莫司类似物及其制备方法和应用
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
CN115097046B
(zh)
*
|
2022-07-07 |
2023-09-26 |
国药集团川抗制药有限公司 |
一种分离雷帕霉素及其杂质的方法
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|